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Objectives: This study aimed to cross-culturally translate the Qualiveen-30 into Persian and validate it in Iranian
patients with spinal cord injury (SCI) and multiple sclerosis (MS).
Methods: This was a cross-sectional prospective validation study. The translation and cross-cultural adaptation of the
original questionnaire was performed in accordance with published guidelines. A total of 154 patients with SCI or MS
who suffered from lower urinary symptoms for at least 6months were asked to complete the questionnaire in the first
visit to the clinic and after 3weeks. To assess reliability, the internal consistency was assessed by Cronbach’s alpha
coefficient, and validity was assessed using convergent and discriminant validities.
Results: The Cronbach’s alpha coefficients for the Qualiveen-30 at two assessments ranged from 0.82 to 0.95,
indicating a good internal consistency for the questionnaire. There were high amounts of test-retest reliability for the
Qualiveen questionnaire and each of its domains (ICC>0.90). Also, Qualiveen and its domains had a moderate to
high correlation with the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form
(ICIQ-UI SF) (0.36< r<0.57) and SF-12 MCS (−0.51< r<−0.11) and SF-12 PCS (−0.29< r<−0.19), indicating
good convergent validity. Comparison of Qualiveen in groups of income, education andmanner of voiding revealed the
high discriminative power of this instrument. The hypothesized four factor structure was approved using confirmatory
factor analysis (CFA).
Conclusions: In general, the Persian version of Qualiveen-30 performed is a reliable and valid measure for the
evaluation of the quality of life related to lower urinary symptoms in patients with SCI or MS.
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1. INTRODUCTION
Today, the quality of life (QoL) in people with multiple
sclerosis (MS) and spinal cord injury (SCI) has become
an important outcome assessment for both treatment and
research.1 It is a major challenge for most healthcare
systems worldwide. Although life expectancy in these
neurological diseases has improved due to healthcare
promotion in the last three decades,2 there are still var-
ious factors such as Urinary Disorders (UD) which are
responsible for a significant negative impact on the QoL
in both SCI and MS.3–5 The symptoms of urinary disor-
ders in this group of patients are common and can present
as a problem in the voiding or storage of urine.6–8
Several specific instruments have been developed and
recommended to evaluate urinary symptoms in patients
with lower urinary tract disorder. These instruments
are Incontinence Quality of Life Instrument (I-QoL),9
Urge Incontinence Impact Questionnaire (Urge-IIQ) and
Urge Urological Distress Inventory (Urge-UDI),10 Over-
active Bladder Questionnaire (OAB-Q),11 International
Consultation on Incontinence Questionnaire-Urinary
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Incontinence Short Form (ICIQ-UI SF)12 and Qualiveen
Questionnaire.13 Although the ICIQ-UI SF, OAB-Q,
Urge-IIQ, Urge-UDI, and I-QoL questionnaires are
helpful to evaluate urinary incontinence symptoms,
Qualiveen is the most UD-specific Health-Related QoL
(HRQoL) instrument. It not only is the most widely
used instrument to evaluate UD-HRQoL in neurologic
patients, but also it is the only questionnaire that
addresses both storage and voiding symptoms.14 Besides,
in the 2011 review of the EAU guidelines, it has been
stated that Qualiveen is the only specific tool for HRQoL
for neurogenic lower urinary tract dysfunction.15
Although the Qualiveen questionnaire was developed
for French-speaking SCI patients,13 it was quickly trans-
lated and validated in English,16 Spanish,17 Portuguese,2
German,18 Turkish19 and Arabic.20 Because of the simi-
larity of urinary problems in patients with SCI and MS,
the Qualiveen questionnaire was validated and used for
patients with MS, as well.16,17,19
In this study, the French version of Qualiveen was
translated to Persian and validated to use in Persian-
speaking patients with neurogenic lower urinary tract
dysfunction. The aim of this study was to translate the
Qualiveen-30 to Persian and to adapt it for patients who
suffer from urinary symptoms and to validate it cross-
culturally for Iranian patients with spinal cord injury and
multiple sclerosis.
2. METHODS
2.1. Patient population
This cross-sectional study was conducted from Novem-
ber 2011 toMay 2012. The study included 154 outpatients
with SCI or MS (80 SCI and 74 MS) who were suffering
from lower urinary tract symptoms for at least 6months.
The participants were selected from two medical centers
that were affiliated with Tehran University of Medical Sci-
ences, the Spinal Cord Injury Clinic at Imam Khomeini
Hospital (BASIR) and the Multiple Sclerosis Clinic at Sina
Hospital (MSRC). These selected centers are two major
referral centers for SCI and MS patients in Iran.
The inclusion criteria were age older than 18 years, abil-
ity to read and speak in Persian, lower urinary tract symp-
toms for at least 6months, suffering from MS based on
the Poser criteria or complete or incomplete SCI accord-
ing to their medical records, no evidence of acute urinary
infection, no symptoms or signs of cognitive impairment,
and consent to participate in the study. Patients with cog-
nitive impairment and pregnant women were excluded.
The study obtained the necessary ethical approval from
the Ethics Committee of Tehran University of Medical
Sciences and all patients signed up an informed consent
form before collecting data.
2.2. Instruments
2.2.1. Qualiveen-30
The Qualiveen is a 30 item questionnaire that focuses
on four aspects of patients’ lives including bother with
limitations (nine items), frequency of limitations (eight
items), fears (eight items), and feelings (five items). The
Qualiveen is a Likert-type questionnaire in which each
question has five options to be answered. The option 0
indicates that urinary problems have no effect on the
quality of life, while option 4 indicates a great adverse
effect on the quality of life of the patients.13 The mean
score of the items in each domain indicates the score for
that domain and the overall score of Qualiveen is the
mean of the four domains.
2.2.2. ICIQ-UI SF
The ICIQ-UI SF is an instrument that was developed to
evaluate the burden of urinary incontinency in patients’
daily life. The ICIQ-UI SF assesses the symptoms that
influence the QoL. It has four questions that evaluate
frequency, severity, effect of incontinence on patients’
QoL and usual urinary leakage situations.12 The ICIQ-UI
SF questionnaire used in this study was its Persian ver-
sion, which had been translated and validated in another
study.21
2.2.3. SF-12 Questionnaire
The SF-12 questionnaire is a short form of the SF-36
questionnaire. The questionnaire has 12 items to examine
two aspects, i.e. physical and psychological aspects, of
QoL. These aspects were summarized into two summary
scores: the physical component summary (PCS-12) and
the mental component summary (MCS). The Persian
version of SF-12 has already been validated and adapted
to Persian-speaking population in another study.22
2.3. The Qualiveen-30 translation procedure
Multi-stage forward-backward-translation procedure,
which is suggested by Beaton et al.,23,24 was followed to
translate the French version of the Qualiveen-30 ques-
tionnaire and obtain the final Persian version of the
questionnaire. Two native Persian-speaking urologists
who were expert in French translated the questionnaire
independently into Persian. Afterward, a professional
interpreter reconciled the translation disparities. Once the
Persian version of the Qualiveen-30 was developed, it was
back-translated into French by a native French speaker
fluent in Persian. The purpose of back-translation was to
ensure the content of the translation remained consistent
with the original version of the questionnaire. Review of
the back-translated version revealed four minor discrep-
ancies that were corrected in the next draft of the Persian
Qualiveen.
In addition, a comaprsion was made between the
back-translated and original French version of the ques-
tionnaire. After a careful review and cultural adaptation,
few changes were made and the provisional draft of
the Persian version of the Qualiveen questionnaire was
provided.
Testing of the provisional draft was performed in a pilot
study with six SCI and fiveMS patients who suffered from
lower urinary tract symptoms to provide feedback regard-
ing the final Persian version of the Qualiveen in order to
© 2014 Wiley Publishing Asia Pty Ltd
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fine-tune the wording of each item. There were two pur-
poses for the fine-tuning process. The first was to make
sure the questionnaire measured what the researchers
intend to examine by the questionnaire and the sec-
ond purpose was to make sure that the patients could
understand and complete the Persian version of the ques-
tionnaire easily. Most patients correctly understood the
questionnaire items and their general comments on the
difficulty of filling out the questionnaire or understanding
each itemwere asked. After a consensus by all researchers,
the final version was developed and used in this study.
2.4. Procedures
The participants were asked to complete the demo-
graphic form, the Persian version of Qualiveen, the Per-
sian version of SF-1225 and the Persian version of ICIQ-UI
SF21 in the first visit after obtaining an informed consent.
The Persian version of Qualiveen with an empty stamped
envelope was posted to the subjects after 3weeks. They
were asked to complete and return the questionnaire to
assess test-retest reliability. Demographic and some clini-
cal characteristic data were collected through a self report
form including age, gender, education, income, marital
status and manner of voiding.
2.5. Statistical analysis
Statistical reliability methods were performed for the
overall score of Persian Qualiveen and its four domains.
Intra-class correlation coefficient (ICC) was used to eval-
uate test-retest reliability. In addition, Cronbach’s alpha
was calculated to assess internal consistency.
Construct validity was assessed by examining the con-
vergent validity and discriminant validity. For convergent
validity, it was hypothesized that the Persian Qualiveen
and its domainswere significantly correlatedwith ICIQ-UI
SF and SF-12 PCS and SF-12 MCS. Pearson’s correlation
coefficient was used for calculating the correlation. For
discriminant validity, it was hypothesized that the Persian
Qualiveen and its domains could be significantly different
in the levels of variables such as the manner of voiding,
age, education and income status. Effect sizes were calcu-
lated using Cohen’s statistic (difference in means divided
by the standard deviation of the difference) to compare
the scores of the Persian version in the categories of ICIQ-
UI and SF-12 PCS and SF-12 MCS scores (<40 vs. ≥40).
The results of the Cohen’s statistic were interpreted as
small, moderate, or large based on values of 0.2, 0.5, and
0.8, respectively.26 Ceiling and floor effects of the Persian
version and its domains were measured at baseline and
follow-up. The ceiling and floor effect less than 15% was
considered an acceptable standard measurement.27
Analysis of variance (ANOVA) or independent-samples
t-test was used to investigate the significant differences
between sample means in this study. The Tukey multiple
comparison method was used for post-hoc analysis. The
normality of the variables was checked by Chapiro-Wilk
test and homogeneity of the variance in the groups was
tested by Levene statistic. SPSS software (version 18, IBM
Corporation, New York, NY, USA) was used for data
analysis. In this study, a P-value<0.05 was considered
statistically significant.
To assess factor structure of the Persian version of the
Qualiveen, confirmatory factor analysis was conducted.
The four factors were restriction, bother with limita-
tions, frequency of limitations, fears, and feelings. The
confirmatory factor analysis (CFA) was estimated using
weighted least squares (WLS). A single-step model (CFA)
was conducted on the entire sample in an attempt to test
the hypothesized structural four-factor structure of the
Qualiveen. Several goodness-of-fit indices were used to
assess the fit of the hypothesized model to the current
sample. The root-mean-square error of approximation
(RMSEA), χ2 statistic, comparative fit index (CFI) and
non-normed fit index (NNFI) were examined. A non-
significant χ2 statistic indicates overall model fit of the
data. However, χ2 statistic is sensitive to sample size.
Therefore, it should be interpreted in conjunction with
other fit indices. A RMSEA value less than or equal to
.08 is considered acceptable, while values equal or higher
than 0.90 for the CFI, NNFI are considered acceptable.28,29
3. RESULTS
Table 1 shows the demographic and clinical character-
istics of the participants. The mean age of the patients was
35.3 years and most of the patients were between 35 and
44 years of age (44.2%). Sixty-five patients (42.2%) were
female. Ninety-eight patients (64.1%) completed high
school diploma or had higher education. The majority
of the patients had moderate income (67.5%) and were
married (66.7%). Thirty-four percent of the patients had
normal voiding with some urinary problems. The distri-
butions of Qualiveen, ICIQ-UI SF and SF12 are depicted
on the box plots in Fig. 1.
3.1. Internal consistency
Cronbach’s alpha coefficient was used to evaluate the
internal consistency of Persian Qualiveen at baseline
and follow-up. Cronbach’s alpha for the overall score
of Persian Qualiveen was 0.95 at two measurements. It
was 0.89 for the ‘‘bother with limitations’’; 0.93 for the
‘‘frequency of limitations’’; 0.89 for the ‘‘fears’’; and 0.85
for the ‘‘feelings’’ domains at baseline. Approximately the
same high values of internal consistency were obtained
at follow up (Table 2).
3.2. Test-retest reliability
Intra-class correlation coefficient was used to calculate
the stability of the questionnaire. There was a high test-
retest reliability for the Qualiveen questionnaire and its
each domains. The ICC value was 0.97 for the total
Qualiveen score, 0.96 for bothers, 0.96 for frequency of
limitations, 0.97 for fears, and 0.94 for feelings domain,
which showed a high reliability (Table 2).
3.3. Convergent validity
As hypothesized, there were positive correlations
between Qualiveen and ICIQ-UI SF (r=0.57) and also
© 2014 Wiley Publishing Asia Pty Ltd
4 Abolghasem Nikfallah et al.
TABLE 1. Demographic and clinical characteristics of patients
Variables n = 154
Gender
Male 89 (57.8)
Female 65 (42.2)
Age (year, mean± SD) 35.33± 9.8
Younger than 25 18 (11.7)
25–34 68 (44.2)
35–44 44 (28.6)
45 and higher 24 (15.6)
Education
Illiterate and primary school 21 (13.7)
Middle and high school 34 (22.2)
High school diploma and college 53 (34.6)
Higher education 45 (29.4)
Income
Good 26 (17.2)
Moderate 102 (67.5)
Poor 23 (15.2)
Marital status
Single 51 (33.3)
Married 102 (66.7)
Manner of voiding
Normal voiding 51 (34.0)
Indwelling catheter 23 (15.3)
Intermittent catheter 30 (20.0)
Condom sheath and napkin 24 (16.0)
Other (Tapping, massage, abdominal pressure, etc.) 22 (14.7)
Values are given as n (%) or mean ± SD.
as expected, higher values of Qualiveen were linearly
associated with lower values of SF-12 MCS and SF-12
PCS, indicating that physical health and mental health,
as general quality of life, was correlated significantly
with urinary disorder specific quality of life r=−0.29
TABLE 2. Descriptive statistics and reliability scale for the Qualiveen
questionnaire
n
Floor
n (%)
Ceiling
n (%)
Cronbach’s
alpha ICC
Qualiveen Baseline 154 0 (0) 0 (0) 0.95 0.97
Follow-up 145 0 (0) 0 (0) 0.95
Bother with
limitations
Baseline 154 1 (0.6) 2 (1.3) 0.89 0.96
Follow-up 145 1 (0.7) 2 (1.4) 0.89
Frequency of
limitations
Baseline 153 2 (1.3) 1 (0.7) 0.93 0.96
Follow-up 145 1 (0.7) 1 (0.7) 0.82
Fears Baseline 153 1 (0.7) 4 (2.6) 0.89 0.97
Follow-up 144 1 (0.7) 5 (3.5) 0.91
Feelings Baseline 153 16 (10.5) 3 (2.0) 0.85 0.94
Follow-up 142 12 (8.5) 4 (2.8) 0.88
and r=−0.32, respectively. The correlation between
the overall score of Qualiveen, domains of Qualiveen,
ICIQ-UI SF and SF-12 MCS and SF-12 PCS is shown in
Table 3.
3.4. Discriminant validity
The overall Qualiveen scores and its each domain
for different grouping variables are shown in Table 4.
As expected, patients with higher levels of education
had significantly better urinary disorder specific quality
of life (P<0.001) and also patients with good income
had better urinary quality of life compared to low and
moderate income patients (P<0.05). As hypothesized,
the manner of voiding has significant effect on patient’s
quality of life. Participants with normal voiding had sig-
nificantly lower values for Qualiveen and all its domains
(P< 0.05).
Fig. 1 Box plots distribution for Qualiveen, International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) and
SF-12.
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3.5. Effect size
Effect size indices, unlike significant tests, are inde-
pendent of the sample size. There are different methods
to achieve them. Standardized differences between two
means were used to calculate the effect size in this study.
Cohen’s d (effect size) can also be interpreted in terms
of non-overlap measures in comparison between two
groups.26 For example, a non-overlap of 0% (equals
with ES of 0.0) indicates that distribution scores for
two groups are completely overlapped. Results from
the known group comparisons between subgroups of
patients formed on the basis of the ICIQ-UI SF and SF-
12 PCS and SF-12 MCS are summarized in Table 5.
The non-overlap measure for overall Qualiveen score
based on ICIQ-UI SF and SF-12 were 65.3 and 27.4%,
respectively.
3.6. Factor structure
The hypothesized four factor structure with 30 items
was tested using the full sample of participants. The results
TABLE 3. Correlation between the Qualiveen questionnaire and its
domains with SF-12 and International Consultation on Incontinence
Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF)
1 2 3 4 5 6 7 8
1. Overall
score of
Qualiveen
1 0.85 0.87 0.82 0.76 −0.29 −0.32 0.57
2. Bother with
limitations
– 1 0.71 0.57 0.46 −0.26 −0.27 0.55
3. Frequency
of limitations
– – 1 0.56 0.59 −0.27 −0.48 0.52
4. Fears – – – 1 0.59 −0.19 −0.51 0.42
5. Feelings – – – – 1 −0.25 −0.29 0.36
6. SF-12 PCS – – – – – 1 −0.11 −0.17
7. SF-12 MCS – – – – – – 1 −0.25
8. ICIQ-UI SF – – – – – – – 1
All Pearson’s (r) coefficient were significant (P< 0.05) except correlation
between SF-12 & ICIQ-UISF.
indicated that the fit model was acceptable (χ2 =815.27,
df= 399, RMSEA=0.078, CFI=0.95, NNFI= 0.94).
TABLE 4. Mean and standard deviation of the Qualiveen in levels of other variables
Qualiveen
Bother with
limitations
Frequency of
limitations Fears Feelings
Mean± SD P-value Mean± SD P-value Mean± SD P-value Mean± SD P-value Mean± SD P-value
Gender
Male 56± 18.8 < 0.001 50.5± 21.1 0.029 59.2± 22.5 < 0.001 63± 24 0.002 49.8± 28.7 < 0.001
Female 42.2± 22.4 42.3± 24.8 43.3± 27.4 47.8± 29.2 32.1± 23.1
Age
Younger than 25 45.5± 24.8 0.579 42± 22 0.192 50.6± 33.3 0.990 50.6± 30.5 0.616 38.5± 26.6 0.972
25–35 51.7± 21.6 50.8± 24.1 52.0± 25.7 68.6± 27.9 42.9± 28.7
35–45 47.6± 18.1 42.5± 20.3 50.4± 24.1 54.5± 24.4 42.1± 26.5
45 and higher 47.5± 24.6 42.2± 25.1 52.2± 26.4 51.7± 28.6 42.0± 32.1
Education
Illiterate and
primary school
55.9± 20.7 0.001 55.2± 23.0 0.011 57.1± 24.1 0.006 62.5± 23.7 0.004 44.8± 27.8 0.015
Middle and high
school
55.3± 18.9 46.4± 22.5 57.2± 23.2 66.2± 22.7 51.8± 27.7
High school
diploma and
college
52.7± 19.8 51.0± 21.4 56.9± 24.9 57.7± 27.4 43.1± 25.8
Higher
education
39.7± 21.9 38.3± 22.7 41.1± 26.5 44.5± 28.0 32.2± 27
Income
Good 39.7± 19.4 0.027 41.2± 21.0 0.363 44.5± 23.5 0.116 38.4± 26.1 < 0.001 29.2± 22.9 0.007
Moderate 52.2± 21.8 47.7± 23.8 53.8± 26.7 60.6± 26.5 45.5± 28.1
Poor 50.6± 19.0 49.5± 20.9 52.6± 23.3 56.6± 25.1 40.9± 27.5
Marital status
Single 53.6± 20.9 0.127 47.6± 22.5 0.761 56.2± 25.6 0.189 62.6± 26.3 0.046 47.5± 27.2 0.078
Married 48.0± 21.3 46.4± 23.2 50.4± 25.7 53.2± 27.2 39.3± 27.4
Manner of voiding
Normal voiding 34.88± 18.39 < 0.001 36.24± 21.91 < 0.001 33.25± 22.74 < 0.001 39.63± 24.42 < 0.001 29.12± 23.53 0.001
Indwelling
catheter
53.89± 19.64 48.55± 20.51 58.02± 22.71 61.36± 26.68 46.52± 26.77
Intermittent
catheter
62.67± 14.87 58.55± 19.44 66.67± 17.55 69.18± 19.98 53.50± 26.40
Condom sheath
and napkin
59.74± 21.60 53.02± 25.72 69.02± 21.11 67.37± 29.27 47.61± 31.37
Other (Tapping,
massage,
abdominal
pressure, etc.)
54.26± 17.78 49.54± 20.18 54.40± 23.18 62.49± 21.31 48.18± 27.93
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4. DISCUSSION
Although many non-specific questionnaires have been
developed to evaluate urinary symptoms in neurological
patients, none can solely evaluate the urinary symptoms-
related QoL in this population. The Qualiveen is a specific
questionnaire that evaluates all aspects of special needs
and complaints of patients with neurological disorders.
The Qualiveen was translated and validated in this study
because there was no available questionnaire to assess
the urinary symptoms-related QoL for Persian-speaking
neurological patients.
The Quliveen was originally designed and used in
western countries13 but it is not extensively used in
eastern cultures.19,20 In particular, people from Middle
Eastern countries have diverse beliefs regarding urinary
problems, which root from their religious perspectives.
Due to cultural and linguistic differences, a rigorous
translation procedure is essential to develop a health-
related QoL questionnaire that is well applicable in a
population with a different culture, beliefs, religion and
language. In this study, a multi-stage forward-backward-
translation procedure, suggested by Beaton et al.,23,24 was
used to guide authors through the process of develop-
ing a normalized sequence for the same questionnaire
for different populations. Participants did not report any
major problems in understanding the Persian version of
Qualiveen-30.
The reliabilty and validaty study revealed that the
Persian version of Qualiveen had a very good inter-
nal consistency with Cronbach’s alpha coefficient greater
than 0.80 for the Qualiveen and all of its domains. In this
study, ICCs for test-retest reliability were greater than
0.90, indicating an excellent test-retest reliability for the
Persian version of Qualiveen-30, which is higher than
all other published studies.2,3,13,17–20 Convergent validity
was measured as the correlation of Qualiveen with ICIQ-
UI SF. A significant correlation was observed between the
Persian version of Qualiveen-30 and ICIQ-UI SF indicat-
ing a good convergent validity. Despite high correlations
between ICIQ-UI SF and Qualiveen-30, relatively weak
correlations were found between both SF-12 MCS and
SF-12 PCS. Maybe, the reason for this is that the SF-12
is a generic tool and not a disease-specific tool to capture
clinical change.
Comparison of Quliveen in categories of the variables,
income, education, and manner of voiding showed the
high discriminative power of this instrument, similar to
the French and English versions.13,16
There is no doubt about the necessity of having a
reliable questionnaire in Persian because of the high
prevalence of SCI, MS and other neurological urinary
disorders in Iran. SCI has a very high prevalence in Iran
due to the high rate of motor vehicle accidents.30 A
study reported a prevalence of 4.4 in 10 000 for SCI in
Tehran (the capital of Iran). In addition, the prevalence
of MS in Iran has been reported from 50.6 to 73.7 in
100 000 in published studies,31,32 summing a total num-
ber with a range of 38 500–56 000 . In addition, Persian is
the official language of two other countries, Afghanistan
© 2014 Wiley Publishing Asia Pty Ltd
Validation of Qualiveen’s Persian Version 7
and Tajikistan, with populations of 34.0 and 7.2 million,
respectively, that can be a target for the Persian version
of Quliveen.33 These countries are culturally very similar
to Iran. There are slight language differences between
Persian-speaking countries, but people in these countries
understand each other very easily. In the translation pro-
cedure, we tried to use the words that are common and
understandable in all Persian-speaking countries. There-
fore, we believe that the Persian version of the Quliveen is
applicable in all Persian-speaking countries. Future stud-
ies should assess the discriminant validity of the Persian
version of the Qualiveen between healthy people with-
out neurogenic bladder and patients with neurogenic
bladders.
The Qualiveen is a comprehensive questionnaire for
QoL evaluation in patients with urinary dysfunction,
which proved useful for SCI and MS patients.The results
showed that the Qualiveen was validated for both SCI
and MS without demonstrating any significant difference
between the two groups. The only inconvenience of the
instrument is its length, but its completeness enables
in-depth evaluation of the patients’ perception, mak-
ing the Qualiveen an excellent instrument for research
trials.
5. CONCLUSION
In conclusion, in this study, the process of translation,
cross-cultural adaptation and validation of the French
Qualiveen questionnaire to Persianwas done successfully.
It is recommended that health centers and clinics use the
Persian version of the Qualiveen in order to assess urinary
symptoms-related QoL in patients with SCI or MS who
suffer from urinary incontinence due to the neurogenic
bladder.
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